TCRT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 04:00):

Stats
今日成交量	25 270.00
平均成交量	76 641.00
市值	20.82M
EPS	$0 ( 2024-04-02 )
下一个收益日期	( $-0.450 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0400
ATR14	$0.0270 (2.05%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Groenewald Ferdinand	Buy	0
2024-01-20	Hogue Dale Curtis Jr.	Buy	600 000	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	150 000	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	41 667	Employee Stock Option (right to buy)
2023-12-29	Hogue Dale Curtis Jr.	Buy	0

INSIDER POWER
96.76
Last 87 transactions
Buy: 16 191 500 \| Sell: 2 243 866

音量相关性

長: 0.06 (neutral)

短: 0.89 (strong)

Signal:(48.737) Same movement expected

Alaunos Therapeutics, 相关性

10 最正相关
WISA	0.942
ALZN	0.935
TTCF	0.935
KVSB	0.932
ALLO	0.931
GH	0.927
ADSE	0.926
AGFY	0.925
COMT	0.925
INFI	0.924

10 最负相关
IBEX	-0.937
ISIG	-0.92
STAY	-0.914
RNLC	-0.913
CCRC	-0.912
SLGN	-0.91
USLB	-0.904
XOMAO	-0.903
SEDG	-0.903
VLYPO	-0.894

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Alaunos Therapeutics, 相关性 - 货币/商品

0.39
( neutral )

0.45
( neutral )

0.00
( neutral )

-0.12
( neutral )

-0.47
( neutral )

Alaunos Therapeutics, 财务报表

Annual	2023
营收:	$5 000.00
毛利润:	$-2.31M (-46 200.00 %)
EPS:	$-2.20

FY	2023
营收:	$5 000.00
毛利润:	$-2.31M (-46 200.00 %)
EPS:	$-2.20

FY	2022
营收:	$2.92M
毛利润:	$163 000 (5.58 %)
EPS:	$-2.60

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.370

Financial Reports:

No articles found.

Alaunos Therapeutics,

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

实时更新： Alaunos Therapeutics, [TCRT]

Upcoming Earnings Alert